Michał Kapałka

Dr. Michał Kapałka

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
GHGrzegorz Hirnle
Grzegorz Hirnle
MKMichał Kapałka
Michał Kapałka
MKMichał Krawiec
Michał Krawiec
THTomasz Hrapkowicz
Tomasz Hrapkowicz
MIMicha
Micha
Introduction: Pericardial mesothelioma is an exceedingly rare pericardial neoplasm. It has atypical clinical symptoms and imaging characteristics that often lead to an inconclusive diagnosis. The diagnosis of a rare tumor such as pericardial mesothelioma, which can present with a variety of manifestations, requires a multidisciplinary approach.Case presentation: A 36-year-old Caucasian female patient without significant past medical history was admitted to the hospital with chest pain and a high fever and was diagnosed with acute pericarditis. The following month, the patient was treated for sepsis; during this hospitalization, lab tests for antinuclear antibodies (ANA) turned out to be positive. Concurrently, mediastinal lymphadenopathy was observed. Given the suspicion of mediastinal lymphoma, a mediastinoscopy with lymph node biopsy was performed. Following a negative biopsy result, positron emission tomography combined with computed tomography (PET/CT) and blood immunophenotyping were performed. Both tests ruled out a diagnosis of lymphoma. Concurrently, the patient was hospitalized in the rheumatology department due to positive ANA results. There, in addition to the ANA titer at a level of 1:320, lupus anticoagulant was detected. The patient was diagnosed with systemic lupus erythematosus (SLE) and initiated on chronic steroid therapy. As heart failure progressed, the patient was admitted to the cardiology department. Tissue Doppler echocardiography and cardiac magnetic resonance imaging (MRI) revealed features indicative of constrictive pericarditis. The patient underwent a pericardiectomy with satisfactory results. However, the pathology result of the pericardium remained equivocal. The patient was readmitted 3 months later with severe circulatory failure, and a salvage procedure of pericardiectomy was performed. Histopathological examination of the sections confirmed the diagnosis of pericardial epithelioid mesothelioma. The patient died after 3 weeks of palliative care.Conclusions: In the differential diagnosis of relapsing and resultant constrictive pericarditis, neoplastic processes that may mimic systemic rheumatic diseases should also be considered. Pericardial mesothelioma is a very rare diagnosis and may result in increased ANA titers, particularly anti-dense fine speckled 70 (DFS70) antibodies.

11 August 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MKMichał Kapałka
Michał Kapałka
EPEstera Pazek
Estera Pazek
MKMichał Krawiec
Michał Krawiec
MSMichał Sikorski
Michał Sikorski
GHGrzegorz Hirnle
Grzegorz Hirnle
THTomasz Hrapkowicz
Tomasz Hrapkowicz
Background: Primary pericardial mesothelioma (PPM) is a rare and aggressive tumor. We aimed to analyze diagnostic pathways and factors influencing survival. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420261277326). MEDLINE, Web of Science, and EMBASE were searched up to March 2025. Case reports and case series published from 2010 onwards de- scribing histologically confirmed PPM were included. Data were extracted independently by multiple reviewers. Risk of bias was assessed using Joanna Briggs Institute tools. Individual patient data were pooled. Survival was analyzed using Kaplan-Meier and log-rank tests, and factors associated with survival ≥12 months were evaluated using univariable logistic regression. Results: A total of 120 patients were included (108 case reports, 4 case series). Diffuse pericardial involvement predominated (74.2%), while localized tumors occurred in 30.8%. Constrictive pericarditis was present in 31.7%. Median overall survival from diagnosis was 7.4 months (IQR 1.75–13.5). Use of CT and PET in the diagnostic process was associated with longer survival (CT: 9.1 vs. 1.5 months, p = 0.02; PET: 14 vs. 6 months, p = 0.04). Chemotherapy was associated with improved survival (OR 3.3; 95% CI 1.3–8.4; p = 0.01). Greater pericardial effusion volume was also associated with longer survival (OR 1.56; 95% CI 1.05–2.32; p = 0.028). Worse outcomes were observed in patients with constrictive pericarditis (p = 0.01) and diffuse disease (p = 0.04). Conclusions: PPM carries a poor prognosis. Chemotherapy and advanced imaging are associated with longer survival, whereas constrictive pericarditis and diffuse involvement indicate worse outcomes. Early recognition may reduce diagnostic delay. Findings should be interpreted with caution due to limitations of case-based data.

15 December 2025 in Annales Academiae Medicae Silesiensis
Verified
Journal Article
Open access
EPEstera Pazek
Estera Pazek
MSMichał Sikorski
Michał Sikorski
MKMichał Kapałka
Michał Kapałka
MKMichał Krawiec
Michał Krawiec
GHGrzegorz Hirnle
Grzegorz Hirnle
THTomasz Hrapkowicz
Tomasz Hrapkowicz
Wstęp: Pierwotny międzybłoniak osierdzia (primary pericardial mesothelioma – PPM) to wyjątkowo rzadki i agresywny nowotwór, wykrywany w mniej niż 0,0022% wszystkich badań autopsyjnych. Ze względu na niespecyficzny przebieg kliniczny oraz podobieństwo objawów do częstszych schorzeń sercowo-płucnych, jego rozpoznanie następuje zwykle w zaawansowanym stadium, co istotnie pogarsza rokowanie. Mediana przeżycia wynosi od 6 do 10 miesięcy. Materiał i metody: Przeprowadzono przegląd literatury dostępnej w bazach PubMed, Medline i Web of Science, obejmujący przypadki PPM opublikowane od stycznia 2015 r. do marca 2025 r. Wyszukiwanie przeprowadzono z użyciem słów kluczowych „primary pericardial mesothelioma”, „pericardial mesothelioma” i „malignant pericardial mesothelioma”. Analizowano dane dotyczące objawów, diagnostyki, leczenia oraz czasu przeżycia pacjentów. Wyniki: Obraz kliniczny PPM jest niespecyficzny i obejmuje wysięk osierdziowy, ból w klatce piersiowej oraz objawy niewydolności serca. Złotym standardem diagnostycznym pozostaje badanie histopatologiczne. Leczenie opiera się na schematach stosowanych w międzybłoniaku opłucnej i obejmuje chemioterapię (cisplatyna + pemetreksed), chirurgię oraz leczenie paliatywne. Nowe metody, takie jak immunoterapia czy inhibitory angiogenezy (np. bewacyzumab), wykazują potencjalną skuteczność. Wnioski: PPM charakteryzuje się trudnościami diagnostycznymi, wysoką śmiertelnością i brakiem jednoznacznych wytycznych terapeutycznych. Wczesna diagnostyka oraz podejście wielomodalne mogą wpływać na poprawę rokowania. Potrzebne są dalsze badania prospektywne i wieloośrodkowe, aby opracować skuteczne strategie leczenia tej rzadkiej jednostki chorobowej.

16 March 2026 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
MKMichał Krawiec
Michał Krawiec
MKMichał Kapałka
Michał Kapałka
GHGrzegorz Hirnle
Grzegorz Hirnle
GSGabriela Skórska
Gabriela Skórska
THTomasz Hrapkowicz
Tomasz Hrapkowicz

18 August 2025 in Frontiers in Pediatrics
Verified
Journal Article
Open access
PDF file
MKMichał Krawiec
Michał Krawiec
JŚJoanna Śliwka
Joanna Śliwka
SPSzymon Pawlak
Szymon Pawlak
MKMichał Kapałka
Michał Kapałka
PHPaulina Hamerling
Paulina Hamerling
THTomasz Hrapkowicz
Tomasz Hrapkowicz
Introduction: Barth syndrome (BTHS) is an ultra-rare genetic disease caused by a mutation in the TAFAZZIN gene, located on the X chromosome. This gene codes for the protein tafazzin, which is involved in the metabolism of the mitochondrial phospholipid - cardiolipin. Symptoms of this genetic defect include dilated cardiomyopathy (DCM), skeletal myopathy, neutropenia, growth retardation, reduced cholesterol levels, increased serum lactic acid levels, and hypoglycemia in the neonatal period.Case description: A Caucasian boy with DCM and left ventricular non-compaction associated with BTHS, caused by a previously unreported variant in the TAFAZZIN gene: NM_000116.4:c.525_533del; NP_000107.1:p.(His176_Phe178del) at NC_000023.11:g.154419607_154419615del, in the exon 6. Due to the patient's heart failure, a mechanical circulatory support (MCS) system was required, followed by orthotopic heart transplantation (OHT). Because of the presence of neutropenia, standard immunosuppressive therapy had to be modified in the postoperative period.Conclusions: A previously unreported mutation is presented, leading to BTHS. This disease can have severe cardiovascular manifestations, requiring MCS and OHT.